StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTIQ) stock

KPTIQOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
Share price
Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Karyopharm Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Karyopharm Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $120.97M, down 11.6% year over year. For fiscal 2025 it was $125.62M, down 12.3% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $161.37M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$125.62M-12.3%
FY2024Dec 31, 2024$143.23M+3.2%
FY2023Dec 31, 2023$138.75M-6.7%
FY2022Dec 31, 2022$148.66M-7.6%
FY2021Dec 31, 2021$160.84M+6.6%
FY2020Dec 31, 2020$150.81M+23.3%
FY2019Dec 31, 2019$122.34M-24.2%
FY2018Dec 31, 2018$161.37M+50.4%
FY2017Dec 31, 2017$107.27M+23.4%
FY2016Dec 31, 2016$86.94M-11.1%
FY2015Dec 31, 2015$97.74M+62.6%
FY2014Dec 31, 2014$60.13M+111.3%
FY2013Dec 31, 2013$28.45M+101.9%
FY2012Dec 31, 2012$14.10M+63.5%
FY2011Dec 31, 2011$8.62M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$28.96M-11.7%
Q1 FY2026Mar 31, 2026$33.80M-2.4%
Q4 FY2025Dec 31, 2025$27.67M-16.9%
Q3 FY2025Sep 30, 2025$30.54M-15.5%
Q2 FY2025Jun 30, 2025$32.79M-14.6%
Q1 FY2025Mar 31, 2025$34.62M-2.3%
Q4 FY2024Dec 31, 2024$33.30M-15.4%
Q3 FY2024Sep 30, 2024$36.13M+1.6%
Q2 FY2024Jun 30, 2024$38.37M+21.9%
Q1 FY2024Mar 31, 2024$35.43M+9.5%
Q4 FY2023Dec 31, 2023$39.38M+27.3%
Q3 FY2023Sep 30, 2023$35.55M+13.4%
Q2 FY2023Jun 30, 2023$31.48M-29.0%
Q1 FY2023Mar 31, 2023$32.34M-23.1%
Q4 FY2022Dec 31, 2022$30.93M-29.7%
Q3 FY2022Sep 30, 2022$31.36M-31.5%
Q2 FY2022Jun 30, 2022$44.31M+30.4%
Q1 FY2022Mar 31, 2022$42.06M+13.5%
Q4 FY2021Dec 31, 2021$44.00M+18.3%
Q3 FY2021Sep 30, 2021$45.81M+23.7%
Q2 FY2021Jun 30, 2021$33.98M-20.2%
Q1 FY2021Mar 31, 2021$37.05M+9.0%
Q4 FY2020Dec 31, 2020$37.19M+17.8%
Q3 FY2020Sep 30, 2020$37.04M+41.0%
Q2 FY2020Jun 30, 2020$42.59M+60.6%
Q1 FY2020Mar 31, 2020$34.00M-10.5%
Q4 FY2019Dec 31, 2019$31.58M-18.8%
Q3 FY2019Sep 30, 2019$26.27M-27.9%
Q2 FY2019Jun 30, 2019$26.52M-40.7%
Q1 FY2019Mar 31, 2019$37.97M-8.1%
Q4 FY2018Dec 31, 2018$38.89M+11.6%
Q3 FY2018Sep 30, 2018$36.43M+44.3%
Q2 FY2018Jun 30, 2018$44.73M+93.5%
Q1 FY2018Mar 31, 2018$41.32M+71.6%
Q4 FY2017Dec 31, 2017$34.83M+68.5%
Q3 FY2017Sep 30, 2017$25.24M+26.9%
Q2 FY2017Jun 30, 2017$23.12M–
Q1 FY2017Mar 31, 2017$24.08M–
Q4 FY2016Dec 31, 2016$20.67M–
Q3 FY2016Sep 30, 2016$19.89M–

More Karyopharm Therapeutics figures

See a number that looks wrong?